Solanezumab, a much acclaimed ‘breakthrough’ drug for treating mild dementia has failed to show promise in the phase III trials. In the phase III trails dubbed as EXPEDITION3 which involved more than 2000 patients, the drug showed no decrease in cognitive decline as compared to placebo or dummy drug. The drug, a monoclonal antibody […]
This post first appeared on Biotechin.asia – Your Daily Biotech And Healthca, please read the originial post: here
